Biosimilar and unbranded insulins: are they actually the same?
"Generic insulin" can mean several different things, and the labels matter for switching and pricing.
Updated August 2026 · 4 min read
The 30-second version
- A biosimilar is highly similar to a reference product with no clinically meaningful safety difference. Interchangeable is a stronger FDA designation that allows pharmacy substitution
- Semglee and Rezvoglar are interchangeable biosimilars of insulin glargine
- An unbranded biologic is the same manufacturer's insulin without the brand name, sometimes at a lower price, but device and NDC can differ
- Never switch concentration, delivery device, or insulin type based on price alone without confirming the dosing plan
What the labels actually mean
A biosimilar is a biologic shown to be highly similar to an FDA-approved reference product, with no clinically meaningful differences in safety, purity, and potency. An FDA-designated interchangeable biosimilar meets additional requirements that permit pharmacy substitution, subject to state law. Semglee, insulin glargine-yfgn, is interchangeable with Lantus. Rezvoglar, insulin glargine-aglr, has also received an interchangeability designation for its reference product.
An unbranded biologic is often the same manufacturer's insulin sold without the brand name, sometimes at a lower list price. It isn't "less real" insulin, but the delivery device, NDC, formulary position, and patient price can differ.
When switching saves money
A lower list price helps most when you pay cash or coinsurance tied to price. It may not help if the branded product is preferred because the plan receives rebates, if the alternative is placed on a worse formulary tier, or if changing the prescription disrupts a copay program you're already using. Always compare the counter price under insurance and as cash before switching.
What to ask the pharmacist
- Is this the same insulin molecule and concentration as my prescription?
- Is it FDA-designated interchangeable with my current product?
- Does state law permit substitution, and will you notify my prescriber?
- Is the delivery pen different, and do I need new teaching or needles?
- What will I pay through insurance versus cash?
- Will this claim count toward my deductible and out-of-pocket maximum?
Don't switch between U-100 and concentrated insulin, or between basal, rapid, regular, NPH, or premixed products, based on price alone. Confirm the exact prescription and dosing plan first.
Sources
- FDA, biosimilar basics
- FDA, Purple Book
- FDA, interchangeable biosimilars
Reading is the second step. Finding out what you qualify for is the first.
Keep reading
Glucagon: the emergency medicine people skip because of cost
Cost should be addressed before the emergency, not during it.
Insulin is not the whole diabetes bill
A person can get insulin for $35 and still not afford the tools needed to dose it safely.
CGM assistance, manufacturer by manufacturer
When a CGM is unaffordable, first figure out whether the problem is no coverage, a high deductible, the wrong benefit channel, or a claim error.
Glucopath is not medical or legal advice. Program rules change. Verify details with the program before you apply, and talk to your healthcare provider about your treatment.